Genetically modified immune cells take on deadly brain tumors
NCT ID NCT04991870
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This early-stage trial tests genetically engineered natural killer (NK) cells in 25 people with recurrent glioblastoma, an aggressive brain cancer. The cells are designed to resist the tumor's defenses. The main goal is to find a safe dose and check for side effects, while also watching for any signs of tumor control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH-MUTANT GRADE 4 ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain tumor virus therapy takes on chemo in Head-to-Head trial
- Could a transplant drug help fight glioblastoma?
- Radioactive antibody and immunotherapy combo targets recurrent brain cancer
- Tailored tumor attack: can custom drug cocktails beat recurrent glioblastoma?
- New drug combo aims to boost immune attack on returning brain tumors
- Second radiation blast targets recurrent brain tumors